WA-VIRTUOZZO
13.6.2022 17:49:06 CEST | Business Wire | Press release
Virtuozzo , the alternative cloud platform leader, today announced it was named Cloud Enabler of the Year during the 19th annual Storage Awards hosted by Storage Magazine . Filling a void in the cloud enablement market, Virtuozzo delivers a robust cloud platform for service providers that is easy to use and manage. The honor recognizes the company’s commitment to enabling these providers to rapidly launch an extensive portfolio of scalable cloud services that are viable, cost-effective alternatives to hyperscaler solutions.
The Storage Awards, also known as the Storries, recognize the finest products, companies, and people revolutionizing storage technology. Winners are chosen by Storage Magazine readers, making it one of the few programs driven by an independent selection committee comprised of users and IT decision makers. Virtuozzo was one of twelve nominees in the Cloud Enabler of the Year category and was a contender in five other categories—including Cloud Company of the Year for which it was named runner-up.
“Winning the Storage Award is an achievement we deeply appreciate,” said Alex Fine, CEO, Virtuozzo. “We understand that the decision was made by IT industry members who work with and understand what cloud solutions need to be, what they should enable to be truly beneficial to end users. We are committed to helping service providers generate revenue through competitive, easy-to-use solutions that offer growth and opportunity. As its adoption continues, we believe that Virtuozzo delivers on that promise.”
Fast, Easy, Lower-Cost Cloud
Virtuozzo delivers everything ranging from Infrastructure-as-a-Service (IaaS) to platform-as-a-Service (PaaS) in a single cloud platform. It is purpose-built for hosting, cloud and managed service providers (HSPs, CSPs, and MSPs) complete with features and functions designed to help them easily implement and manage extensive, scalable cloud product portfolios. The simplicity of Virtuozzo frees service providers to focus on differentiating products as well as hands-on customer support—enabling them to quickly reach profitability while helping their users maximize their cloud investments.
Further, Virtuozzo offers its partners a full suite of professional services that help them go to market quickly and efficiently. These include Product Installation, Managed Cloud, Training, and Consulting among others—establishing a true, mutually beneficial collaboration.
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) provides the leading alternative cloud platform for service providers, enabling them to sell cloud services that are more accessible, more affordable and easier to use than hyperscaler solutions. The company’s legacy includes developing the first commercially available container technology and being a major contributor to numerous virtualization and open-source projects for more than 20 years. Today, Virtuozzo cloud solutions are used by more than 700 Cloud Service Providers, Managed Service Providers and Hosting Providers in 80 countries. Virtuozzo is based in Schaffhausen, Switzerland, and has more than 320 employees across the U.S., UK, Europe, and Asia-Pacific.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005614/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom